BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the expression and prognostic roles of human ether à go-go related gene (hERG1) potassium channels in resected esophageal squamous cell carcinoma. METHODS: Expression of hERG1 protein and mRNA was detected by immunohistochemistry and reverse transcription PCR in resected esophageal squamous cell carcinomas (ESCCs) and non-cancerous matched tissues, and the correlation was examined between expression of hERG1 protein and clinicopathological factors and prognosis of ESCC patients. RESULTS: Frequency of positive expression of hERG1 protein was 77.9% (53/68), mRNA was 81.8% (9/11). hERG1 protein and mRNA were negatively expressed in all non-cancerous matched tissues. There was no significant correlation between hERG1 protein expression and lymph node metastases, depth of penetration, stage, and other clinicopathological factors. Completeness was 92.5% for hERG1-positive group and 92.0% for hERG1-negative group. ESCC patients with positive expression of hERG1 protein had a significantly shorter postoperative survival time than those with negative expression (median, 30 vs. 56 months). Survival rates at each time-point for hERG1-positive group were lower than that for hERG1-negative group, and hERG1 was identified as an independent prognostic factor of long-term survival by multivariate analysis. CONCLUSION: In ESCC, hERG1 was aberrantly expressed and correlated with poor prognosis after surgery. (c) 2007 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the expression and prognostic roles of human ether à go-go related gene (hERG1) potassium channels in resected esophageal squamous cell carcinoma. METHODS: Expression of hERG1 protein and mRNA was detected by immunohistochemistry and reverse transcription PCR in resected esophageal squamous cell carcinomas (ESCCs) and non-cancerous matched tissues, and the correlation was examined between expression of hERG1 protein and clinicopathological factors and prognosis of ESCC patients. RESULTS: Frequency of positive expression of hERG1 protein was 77.9% (53/68), mRNA was 81.8% (9/11). hERG1 protein and mRNA were negatively expressed in all non-cancerous matched tissues. There was no significant correlation between hERG1 protein expression and lymph node metastases, depth of penetration, stage, and other clinicopathological factors. Completeness was 92.5% for hERG1-positive group and 92.0% for hERG1-negative group. ESCC patients with positive expression of hERG1 protein had a significantly shorter postoperative survival time than those with negative expression (median, 30 vs. 56 months). Survival rates at each time-point for hERG1-positive group were lower than that for hERG1-negative group, and hERG1 was identified as an independent prognostic factor of long-term survival by multivariate analysis. CONCLUSION: In ESCC, hERG1 was aberrantly expressed and correlated with poor prognosis after surgery. (c) 2007 Wiley-Liss, Inc.
Authors: Sofía T Menéndez; M Ángeles Villaronga; Juan P Rodrigo; Saúl Álvarez-Teijeiro; Rocío G Urdinguio; Mario F Fraga; Carlos Suárez; Juana M García-Pedrero Journal: Sci Rep Date: 2016-01-20 Impact factor: 4.379
Authors: David M Pier; George S G Shehatou; Susan Giblett; Christine E Pullar; Derek J Trezise; Catrin A Pritchard; R A John Challiss; John S Mitcheson Journal: Mol Pharmacol Date: 2014-05-15 Impact factor: 4.436
Authors: Elena Lastraioli; Tiziano Lottini; Lapo Bencini; Marco Bernini; Annarosa Arcangeli Journal: Biomed Res Int Date: 2015-08-03 Impact factor: 3.411